hydroxyurea has been researched along with Leukemia in 106 studies
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro." | 9.13 | Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. ( Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008) |
| " The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)." | 9.10 | Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 7.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients." | 7.69 | Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997) |
| "Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary." | 5.27 | Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984) |
| "1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro." | 5.13 | Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. ( Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008) |
| " The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)." | 5.10 | Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "To compare by a prospective study in high risk polycythemia vera (PV) patients 33P alone and 32P followed by low-dose hydroxyurea (HU) maintenance therapy." | 5.08 | [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age]. ( Dupuy, E; Goguel, A; Grange, MJ; Mougeot-Martin, M; Najean, Y; Rain, JD; Vigneron, N, 1998) |
| "A 62-year-old man with refractory leukemia transformed from myelodysplastic syndrome was placed on hydroxyurea (hydroxycarbamide) at a daily dose of 500 mg." | 4.90 | [Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test]. ( Karigane, D; Kikuchi, T; Koda, Y; Mori, T; Nakajima, H; Okamoto, S; Shimizu, T; Toyama, T, 2014) |
| " Purine antimetabolites used in the treatment of leukemia can be grouped into three classes: (1) structural analogs of normal purines (6-mercaptopurine and 6-thioguanine); (2) inhibitors of de novo purine biosynthesis (methotrexate and hydroxyurea); and (3) inhibitors of purine salvage (2'-deoxycoformycin)." | 4.77 | Purine metabolism as a target for leukemia chemotherapy. ( Brouns, MC; Fitchen, JH; Riscoe, MK, 1989) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 3.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients." | 3.69 | Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997) |
| "While studying the effects of chemotherapy on glucocorticoid receptor (GR) binding levels in hematological malignancies, we observed a sizable increase in nuclear GR binding of [3H]dexamethasone in peripheral leukocytes from a chronic basophilic leukemia patient following treatment with hydroxyurea plus prednisone, but not after prednisone alone." | 3.67 | Elevated glucocorticoid receptor binding in cultured human lymphoblasts following hydroxyurea treatment: lack of effect on steroid responsiveness. ( Greipp, PR; Hoagland, HC; Littlefield, BA, 1986) |
| "The induction of erythroid differentiation in the T3-C12 clone of Friend leukemia cells by dimethyl sulfoxide is accompanied by reduction in viral RNA-dependent DNA polymerase activity with increased cellular delta-aminolevulinic acid synthetase activity and hemoglobin synthesis." | 3.65 | Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors. ( Buell, DN; Ebert, PS; Wars, I, 1976) |
| "Acetohydroxamic acid has been identified, by paper chromatography, in the blood of three patients with chronic myelogenous leukemia on hydroxyurea therapy." | 3.64 | HYDROXYUREA: MECHANISM OF ACTION. ( CARBONE, PP; FISHBEIN, WN, 1963) |
| "Hyperleukocytosis is defined as a white blood cell count greater than 100." | 2.58 | The management of hyperleukocytosis in 2017: Do we still need leukapheresis? ( Korkmaz, S, 2018) |
| "Hyperleukocytosis, arbitrarily defined in acute leukemia as a white blood cell count greater than 100,000/mL, often is associated with increased morbidity and mortality in patients with leukemic processes." | 2.48 | Hyperleukocytosis, leukostasis and leukapheresis: practice management. ( Becker, J; Ganzel, C; Lazarus, HM; Mintz, PD; Rowe, JM, 2012) |
| "Hydroxyurea has proven clinical efficacy for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome." | 2.45 | Advances in the use of hydroxyurea. ( Aygun, B; Ware, RE, 2009) |
| "Hydroxyurea (HU) has a limited, if any, leukemogenic potential and should be considered the current cytotoxic drug for patients at high risk for thrombotic complications, ie, those with age above 60 years or previous thrombotic events." | 2.42 | The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? ( Barbui, T, 2004) |
| "Its use in the treatment of essential thrombocythemia began later in 1950." | 2.41 | Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000) |
| "Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "Acute leukemia is an uncommon complication of patients with essential thrombocythemia (ET)." | 1.33 | Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. ( Lee, LH; Wong, GC, 2006) |
| "The median age at malignancy diagnosis was 34 years (range, 14 months-62 years)." | 1.32 | Malignancy in patients with sickle cell disease. ( Schultz, WH; Ware, RE, 2003) |
| " Thus, the efficacy of other antileukemic agents combined with ZOL should be evaluated experimentally." | 1.32 | Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. ( Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T, 2004) |
| " The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph(+) leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y." | 1.31 | In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. ( Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S, 2001) |
| "Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary." | 1.27 | Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984) |
| "Cytogenetic studies of chronic myelogenous leukemia (CML) have shown that the majority of hemopoietic cells originate from pluripotential stem cells affected in this disease." | 1.26 | Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia. ( Brattain, MG; Coleman, MS; Crist, WM; Sarrif, A; Vinson, PC; Vogler, LB, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (44.34) | 18.7374 |
| 1990's | 20 (18.87) | 18.2507 |
| 2000's | 29 (27.36) | 29.6817 |
| 2010's | 7 (6.60) | 24.3611 |
| 2020's | 3 (2.83) | 2.80 |
| Authors | Studies |
|---|---|
| Torre, EA | 1 |
| Kersh, AE | 1 |
| Fischer, AS | 1 |
| Xu, X | 1 |
| Rosenbach, M | 1 |
| Shields, BE | 1 |
| Hobbs, LK | 1 |
| Carr, PC | 1 |
| Gru, AA | 1 |
| Flowers, RH | 1 |
| Choi, HS | 1 |
| Hong, J | 1 |
| Hwang, SM | 1 |
| Lee, JH | 1 |
| Ma, Y | 1 |
| Kim, SA | 1 |
| Lee, JY | 1 |
| Lee, JO | 1 |
| Bang, SM | 1 |
| Rider, TG | 1 |
| George, SMC | 1 |
| Batool, A | 1 |
| Tidbury, HL | 1 |
| Grace, RJ | 1 |
| Newman, JA | 1 |
| Ali, Z | 1 |
| Felton, JR | 1 |
| Korkmaz, S | 1 |
| Shimizu, T | 1 |
| Mori, T | 1 |
| Karigane, D | 1 |
| Kikuchi, T | 1 |
| Koda, Y | 1 |
| Toyama, T | 1 |
| Nakajima, H | 1 |
| Okamoto, S | 1 |
| Roufosse, F | 1 |
| Li, QB | 1 |
| Li, L | 1 |
| You, Y | 1 |
| Chen, ZC | 1 |
| Xia, LH | 1 |
| Zou, P | 1 |
| Ware, RE | 2 |
| Aygun, B | 1 |
| Mai, X | 1 |
| Lu, X | 1 |
| Xia, H | 1 |
| Cao, Y | 1 |
| Liao, Y | 1 |
| Lv, X | 1 |
| Ganzel, C | 1 |
| Becker, J | 1 |
| Mintz, PD | 1 |
| Lazarus, HM | 1 |
| Rowe, JM | 1 |
| Lu, XZ | 1 |
| Cai, XH | 1 |
| Ma, LD | 1 |
| Chen, BA | 1 |
| Ellis, AK | 1 |
| Lee, DH | 1 |
| Spell, DW | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| FISHBEIN, WN | 1 |
| CARBONE, PP | 1 |
| ORIGENES, ML | 1 |
| BEATTY, EC | 1 |
| BRUBAKER, C | 1 |
| HAMMOND, D | 1 |
| HARTMANN, JR | 1 |
| SHORE, N | 1 |
| WILLIAMS, KO | 1 |
| STEARNS, B | 1 |
| LOSEE, KA | 1 |
| BERNSTEIN, J | 1 |
| FERNBACH, DJ | 1 |
| SHULLENBERGER, CC | 1 |
| KRAKOFF, IH | 1 |
| SAVEL, H | 1 |
| MURPHY, ML | 2 |
| GOLDIN, A | 1 |
| VENDITTI, JM | 1 |
| MEAD, JA | 1 |
| GLYNN, JP | 1 |
| Schultz, WH | 1 |
| Kimura, S | 1 |
| Kuroda, J | 1 |
| Segawa, H | 1 |
| Sato, K | 1 |
| Nogawa, M | 1 |
| Yuasa, T | 1 |
| Ottmann, OG | 1 |
| Maekawa, T | 1 |
| Barbui, T | 6 |
| Bilousova, G | 1 |
| Marusyk, A | 1 |
| Porter, CC | 1 |
| Cardiff, RD | 1 |
| DeGregori, J | 1 |
| Burkitt, MJ | 1 |
| Raafat, A | 1 |
| Kiladjian, JJ | 2 |
| Rain, JD | 3 |
| Bernard, JF | 1 |
| Briere, J | 3 |
| Chomienne, C | 1 |
| Fenaux, P | 1 |
| Silver, RT | 2 |
| Wong, GC | 1 |
| Lee, LH | 1 |
| Dubowy, R | 1 |
| Graham, M | 1 |
| Hakami, N | 1 |
| Kletzel, M | 1 |
| Mahoney, D | 1 |
| Newman, E | 1 |
| Ravindranath, Y | 1 |
| Camitta, B | 1 |
| Lomen, PL | 1 |
| Khilanani, P | 1 |
| Kessel, D | 1 |
| Böhmer, RM | 1 |
| Donovan, PB | 3 |
| Kaplan, ME | 2 |
| Goldberg, JD | 3 |
| Tatarsky, I | 1 |
| Najean, Y | 2 |
| Silberstein, EB | 1 |
| Knospe, WH | 1 |
| Laszlo, J | 1 |
| Mack, K | 2 |
| Berk, PD | 3 |
| Pfeifle, CE | 2 |
| Howell, SB | 2 |
| Streifel, JA | 1 |
| Paton, CM | 1 |
| Bishop, JF | 1 |
| Mathews, JD | 1 |
| Whiteside, MG | 1 |
| Silver, FS | 1 |
| Espinoza, LR | 1 |
| Hartmann, RC | 1 |
| Abe, I | 1 |
| Saito, S | 1 |
| Hori, K | 1 |
| Suzuki, M | 1 |
| Sato, H | 1 |
| Passe, S | 1 |
| Miké, V | 1 |
| Mertelsmann, R | 1 |
| Gee, TS | 2 |
| Clarkson, BD | 2 |
| Chapman, RS | 1 |
| Chresta, CM | 1 |
| Herberg, AA | 1 |
| Beere, HM | 1 |
| Heer, S | 1 |
| Whetton, AD | 1 |
| Hickman, JA | 1 |
| Dive, C | 1 |
| Ho, PT | 1 |
| Murgo, AJ | 1 |
| Weinfeld, A | 1 |
| Swolin, B | 1 |
| Westin, J | 1 |
| Boivin, P | 1 |
| Fitzgerald, JM | 1 |
| McCann, SR | 1 |
| Nand, S | 2 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 2 |
| Finazzi, G | 4 |
| Dupuy, E | 2 |
| Liozon, E | 1 |
| Brigaudeau, C | 1 |
| Trimoreau, F | 1 |
| Desangles, F | 1 |
| Fermeaux, V | 1 |
| Praloran, V | 1 |
| Bordessoule, D | 1 |
| Tóth, G | 1 |
| Schlammadinger, J | 1 |
| Sipka, S | 1 |
| Kiss, A | 1 |
| Szegedi, G | 1 |
| Rák, K | 1 |
| Szabó, G | 1 |
| Pearson, TC | 1 |
| Green, AR | 1 |
| Reilly, JT | 1 |
| Harrisoni, G | 1 |
| Cory, AH | 1 |
| He, AW | 1 |
| Cory, JG | 1 |
| Randi, ML | 2 |
| Rossi, C | 1 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Berlin, NI | 2 |
| Tefferi, A | 1 |
| Solberg, LA | 1 |
| Silverstein, MN | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Ahlmann, M | 1 |
| Lanvers, C | 1 |
| Lümkemann, K | 1 |
| Rössig, C | 1 |
| Freund, A | 1 |
| Baumann, M | 1 |
| Boos, J | 1 |
| Kano, Y | 1 |
| Akutsu, M | 1 |
| Tsunoda, S | 1 |
| Mano, H | 1 |
| Sato, Y | 1 |
| Honma, Y | 1 |
| Furukawa, Y | 1 |
| Guilmin, F | 1 |
| Goguel, A | 1 |
| Grange, MJ | 1 |
| Vigneron, N | 1 |
| Mougeot-Martin, M | 1 |
| Ikeda, Y | 1 |
| de Montalembert, M | 1 |
| Davies, SC | 1 |
| Mavrogianni, D | 1 |
| Viniou, N | 1 |
| Michali, E | 1 |
| Terpos, E | 1 |
| Meletis, J | 1 |
| Vaiopoulos, G | 1 |
| Madzourani, M | 1 |
| Pangalis, G | 1 |
| Yataganas, X | 1 |
| Loukopoulos, D | 1 |
| Ebert, PS | 1 |
| Wars, I | 1 |
| Buell, DN | 1 |
| Berg, J | 1 |
| Vincent, PC | 4 |
| Gunz, FW | 5 |
| Vogler, LB | 1 |
| Crist, WM | 1 |
| Vinson, PC | 1 |
| Sarrif, A | 1 |
| Brattain, MG | 1 |
| Coleman, MS | 1 |
| Wollner, N | 1 |
| Lieberman, P | 1 |
| Exelby, P | 1 |
| D'angio, G | 1 |
| Burchenal, J | 1 |
| Fang, S | 1 |
| Chusid, MJ | 1 |
| Dale, DC | 1 |
| MacEwen, EG | 1 |
| Drazner, FH | 1 |
| McClelland, AJ | 1 |
| Wilkins, RJ | 1 |
| Liang, R | 1 |
| Chan, TK | 1 |
| Chiu, E | 1 |
| Todd, D | 1 |
| Grossi, A | 1 |
| Vannucchi, AM | 1 |
| Longo, G | 1 |
| Rafanelli, D | 1 |
| Rossi Ferrini, P | 1 |
| Schafer, AI | 1 |
| van den Anker-Lugtenburg, PJ | 1 |
| Sizoo, W | 1 |
| Messmore, H | 1 |
| Bird, ML | 1 |
| Schulz, W | 1 |
| Fisher, RI | 1 |
| Löfvenberg, E | 1 |
| Nordenson, I | 1 |
| Wahlin, A | 1 |
| Hedley, D | 1 |
| Rugg, C | 1 |
| Musgrove, E | 1 |
| Taylor, I | 1 |
| Kubota, M | 2 |
| Takimoto, T | 2 |
| Tanizawa, A | 2 |
| Akiyama, Y | 2 |
| Mikawa, H | 2 |
| Kitoh, T | 1 |
| Kiriyama, Y | 1 |
| Riscoe, MK | 1 |
| Brouns, MC | 1 |
| Fitchen, JH | 1 |
| Fruchtman, SM | 1 |
| Wasserman, LR | 2 |
| Landaw, SA | 1 |
| Littlefield, BA | 1 |
| Hoagland, HC | 1 |
| Greipp, PR | 1 |
| Fram, RJ | 1 |
| Kufe, DW | 1 |
| Levi, JA | 3 |
| Smith, RG | 1 |
| Whang-Peng, J | 1 |
| Gallo, RC | 1 |
| Levine, P | 1 |
| Ting, RC | 1 |
| Pouillart, P | 1 |
| Schwarzenberg, L | 2 |
| Mathé, G | 2 |
| Schneider, M | 2 |
| Jasmin, C | 1 |
| Hayat, M | 1 |
| Weiner, R | 1 |
| de Vassal, F | 1 |
| Amiel, JL | 2 |
| Beyer, HP | 1 |
| Fajbisowicz, S | 1 |
| Dowling, MD | 1 |
| Haghbin, M | 1 |
| Cunningham, B | 1 |
| Tan, CT | 1 |
| Burchenal, JH | 1 |
| Prandota, J | 1 |
| Brunning, RD | 1 |
| Maurice, PA | 1 |
| Lederrey, C | 1 |
| Cattan, A | 1 |
| Schlumberger, JR | 1 |
| Benckhuijsen, C | 1 |
| Kovaleva, LG | 1 |
| Konior, GS | 1 |
| Yarbro, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897] | Phase 4 | 360 participants | Interventional | 2003-07-31 | Completed | ||
| Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241] | Phase 2 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for hydroxyurea and Leukemia
| Article | Year |
|---|---|
Case and review: Cutaneous involvement by chronic neutrophilic leukemia vs Sweet syndrome- A diagnostic dilemma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Decitabine; Diagnosis, Di | 2021 |
The management of hyperleukocytosis in 2017: Do we still need leukapheresis?
Topics: Acute Disease; Female; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocy | 2018 |
[Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test].
Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Fatal Outcome; Humans; Hydroxyurea; I | 2014 |
Management of Hypereosinophilic Syndromes.
Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesy | 2015 |
Advances in the use of hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Bone Marrow Diseases; Child; Clini | 2009 |
Hyperleukocytosis, leukostasis and leukapheresis: practice management.
Topics: Acute Disease; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocyte Count | 2012 |
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; | 2004 |
Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders.
Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Myeloproliferative Disorders; Nitric | 2006 |
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
Treatment of polycythemia vera.
Topics: Antineoplastic Agents; Aspirin; Female; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Leukemia; | 2006 |
Evolving management of essential thrombocythaemia.
Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Thrombocythemia, Essential; Thrombos | 2007 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
Treatment of essential thrombocythemia with special emphasis on leukemogenic risk.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Middle Aged; Risk Factors; Thrombocytosis; Thr | 1999 |
Treatment of the myeloproliferative disorders with 32P.
Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D | 2000 |
A clinical update in polycythemia vera and essential thrombocythemia.
Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal | 2000 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials | 2000 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
[Essential thrombocythemia: conventional therapy].
Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo | 1991 |
Essential thrombocythemia.
Topics: Abortion, Habitual; Age Factors; Blood Platelets; Combined Modality Therapy; Diagnosis, Differential | 1991 |
Purine metabolism as a target for leukemia chemotherapy.
Topics: Antineoplastic Agents; Drugs, Investigational; Humans; Hydroxyurea; Leukemia; Mercaptopurine; Methot | 1989 |
[Chemotherapy of chronic leukemias].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Chronic Disease; Cyclophosphamide; Humans; Hydroxyure | 1974 |
Chemotherapy and the life cycle of leukaemic cells. A comparison between the growth characteristics of human acute leukaemia and the murine leukaemia L 1210.
Topics: Anilides; Animals; Cell Division; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans; | 1969 |
[Cytostatic therapy of acute leukemia (review of the literature)].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Drug | 1969 |
9 trials available for hydroxyurea and Leukemia
| Article | Year |
|---|---|
Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
Topics: Adolescent; Adult; Child; Child, Preschool; Cytarabine; Humans; Hydroxyurea; Infections; Leukemia; L | 2008 |
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
Topics: Adult; Aged; Azacitidine; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Humans; | 1980 |
Immunotherapy maintenance in acute non-lymphocytic leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 1982 |
Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
Topics: Acute Disease; Adult; Aged; Bone Marrow; Humans; Hydroxyurea; Leukemia; Middle Aged; Myeloproliferat | 1994 |
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra | 1993 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
[Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Female; Humans; Hydroxyurea; Leukemia; Male; Pho | 1998 |
Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chromosomes, Human, Pai | 2002 |
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Topics: Acute Disease; Age Factors; Bloodletting; Chlorambucil; Combined Modality Therapy; False Positive Re | 1986 |
73 other studies available for hydroxyurea and Leukemia
| Article | Year |
|---|---|
Angiokeratoma-like purpuric palmar nodules following chemotherapy.
Topics: Angiokeratoma; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, | 2021 |
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
Image Gallery: A case of chronic eosinophilic leukaemia.
Topics: Aged; Antineoplastic Agents; Exanthema; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Leukemia; M | 2017 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine | 2009 |
Synthesis, antitumor evaluation and crystal structure of hydroxyurea derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Humans; Hyd | 2010 |
[NKG2D-mediated natural killer cell cytotoxicity against myeloid leukemia cells OUN-1].
Topics: Cell Line, Tumor; Humans; Hydroxyurea; Killer Cells, Natural; Leukemia; Ligands; NK Cell Lectin-Like | 2012 |
Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera.
Topics: Aged; Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Male; Polycythemia Vera; Tumor | 2002 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia; Myelodysplastic Syndromes | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
HYDROXYUREA: MECHANISM OF ACTION.
Topics: Blood Chemical Analysis; Chromatography; Humans; Hydroxamic Acids; Hydroxyurea; Leukemia; Leukemia, | 1963 |
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN.
Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi | 1964 |
HYDROXYUREA. A NEW TYPE OF POTENTIAL ANTITUMOR AGENT.
Topics: Animals; Antineoplastic Agents; Hydroxyurea; Leukemia; Leukemia L1210; Leukemia, Experimental; Mice; | 1963 |
PEDIATRIC CLINICAL TRIALS WITH HYDROXYUREA (NSC-32065).
Topics: Adolescent; Antineoplastic Agents; Child; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Neop | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: LEUKEMIA.
Topics: Antineoplastic Agents; Drug Therapy; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; L | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CLINICAL EVALUATION.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leu | 1964 |
ANTILEUKEMIC ACTIVITY OF HYDROXYUREA (NSC-32065) AND OTHER UREA DERIVATIVES.
Topics: Antineoplastic Agents; Biological Assay; Hydroxyurea; Leukemia; Leukemia, Experimental; Mice; Resear | 1964 |
Malignancy in patients with sickle cell disease.
Topics: Adolescent; Adult; Age of Onset; Anemia, Sickle Cell; Child; Child, Preschool; Data Collection; Huma | 2003 |
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorub | 2004 |
Impaired DNA replication within progenitor cell pools promotes leukemogenesis.
Topics: Animals; Cell Transformation, Neoplastic; Cells, Cultured; DNA; DNA Replication; E2F1 Transcription | 2005 |
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, | 2006 |
Two-step cell-death kinetics in vitro during cis-platinum, hydroxyurea and mitomycin incubation.
Topics: Antibiotics, Antineoplastic; Cell Line; Cell Survival; Cisplatin; Flow Cytometry; Humans; Hydroxyure | 1984 |
Treatment of polycythemia vera with hydroxyurea.
Topics: Acute Disease; Aged; Bone Marrow; Female; Humans; Hydroxyurea; Leukemia; Leukopenia; Male; Middle Ag | 1984 |
Phase I trial of cytarabine and hydroxyurea.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Child; Cy | 1983 |
Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine.
Topics: Arabinofuranosylcytosine Triphosphate; Cell Line; Cytarabine; Deoxyribonucleotides; DNA; Drug Therap | 1982 |
Acral erythema and hydroxyurea.
Topics: Aged; Female; Humans; Hydroxyurea; Leukemia; Raynaud Disease | 1983 |
Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Division; Cell Line; Cells, Cultured | 1982 |
Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined | 1982 |
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells.
Topics: Abelson murine leukemia virus; Antineoplastic Agents; Apoptosis; Cell Nucleus; DNA Damage; DNA Nucle | 1995 |
Hydroxyurea and sickle cell crisis.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Randomized Controlled Trials as Topic | 1995 |
Hydroxyurea and sickle cell crisis.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Pain; Polycythemia Vera | 1995 |
The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
Topics: Adult; Combined Modality Therapy; Female; Humans; Hydroxyurea; Immunologic Factors; Incidence; Infan | 1993 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.
Topics: Aged; Antisickling Agents; Cell Transformation, Neoplastic; Chromosome Aberrations; Female; Humans; | 1997 |
Different effects of an oligonucleotide uptake stimulating protein on leukemic cells in their primitive and differentiated state.
Topics: Biological Transport; Cell Differentiation; Cell Division; Cytarabine; DNA-Binding Proteins; Fungal | 1998 |
Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Pipobroman; Polycythemia Vera | 1998 |
Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Division; Deoxyadenosines; Drug Resistance; Enzyme Inhibitors; | 1998 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
Topics: Adult; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; HL-60 Cells; Humans; Hydroxyure | 2001 |
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Int | 2001 |
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up | 2001 |
[How should patients with essential thrombocythemia be treated?].
Topics: Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxyurea; Leukemia; Platelet Aggregation Inh | 2001 |
Is hydroxyurea leukemogenic in children with sickle cell disease?
Topics: Adolescent; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Leukemia | 2001 |
Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors.
Topics: 5-Aminolevulinate Synthetase; Antimetabolites; Cell Differentiation; Cell Line; Clone Cells; Cyclohe | 1976 |
Extreme leucocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hu | 1979 |
Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia.
Topics: B-Lymphocytes; Cell Transformation, Neoplastic; Child; Chromosomes, Human, 21-22 and Y; Humans; Hydr | 1979 |
Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Child; Child, Preschool; Cyclophosp | 1975 |
The place of research in hospital medicine.
Topics: Acute Disease; Australia; Cell Division; History, 20th Century; Hospital Administration; Hospitals, | 1975 |
Eosinophilic leukemia. Remission with vincristine and hydroxyurea.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Eosinophils; Humans; Hydroxyurea; Le | 1975 |
Treatment of basophilic leukemia in a dog.
Topics: Animals; Basophils; Bone Marrow; Bone Marrow Cells; Busulfan; Dog Diseases; Dogs; Erythrocyte Count; | 1975 |
Non-aggressive therapy for chronic myeloid leukaemia in blastic transformation.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1992 |
Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Middle Aged; Myelodysplastic Syndromes; Thromb | 1990 |
Leukemic transformation in polycythemia vera: analysis of risk factors.
Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Male; Middle Aged; Polycythemia Vera; Retrospe | 1990 |
Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chronic Disease; Female; Humans; Hydroxyurea | 1990 |
Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
Topics: Animals; Cell Line; Cell Survival; Deferoxamine; DNA Replication; Flow Cytometry; Fluorescence; Huma | 1985 |
Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; B-Lymphocytes; Cell Line; Cytarabine; Deo | 1988 |
Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Deoxycytidine; Deoxycytosine | 1989 |
Acute leukemia in polycythemia vera.
Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di | 1986 |
Elevated glucocorticoid receptor binding in cultured human lymphoblasts following hydroxyurea treatment: lack of effect on steroid responsiveness.
Topics: Cell Cycle; Cell Survival; Cells, Cultured; Dexamethasone; DNA; Glucocorticoids; HeLa Cells; Humans; | 1986 |
Long-term management of polycythemia vera with hydroxyurea: a progress report.
Topics: Drug Administration Schedule; Humans; Hydroxyurea; Leukemia; Polycythemia Vera; Thrombosis | 1986 |
Effect of 1-beta-D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts.
Topics: Cells, Cultured; Cytarabine; DNA; DNA Repair; DNA, Single-Stranded; Humans; Hydroxyurea; Leukemia; X | 1985 |
Combination chemotherapy of adult acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hyd | 1972 |
Selective toxicity of rifamycin derivatives for leukaemic human leucocytes.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Bone Marrow Cells; Carbon Isotopes; Cell Differentiation; | 1972 |
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D | 1972 |
The outlook for the adult with acute leukaemia, 1972.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female; | 1972 |
Optimism in leukemia treatment.
Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, | 1973 |
Proceedings: Treatment of acute leukaemia in adults.
Topics: Acute Disease; Adult; Allopurinol; Anti-Bacterial Agents; Bacterial Infections; Child; Cytarabine; D | 1974 |
Comparative results obtained in the treatment of acute leukemia.
Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination | 1973 |
The effects of leukemia and lymphoma chemotherapy on hematopoietic cells.
Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Asparaginase; Cell Division; Daunorubicin | 1973 |
[Repair synthesis of DNA in normal and leukemic lymphocytes damaged by an alkylating agent. Inhibition of repair synthesis by caffeine. Preliminary report].
Topics: Alkylating Agents; Caffeine; Cells, Cultured; DNA; DNA Repair; Humans; Hydroxyurea; Leukemia; Lympho | 1974 |
[Personal experience on the chemotherapy of leukemias and hematosarcomas].
Topics: Antineoplastic Agents; Drug Synergism; Hodgkin Disease; Humans; Hydrazines; Hydroxyurea; Leukemia; L | 1968 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L | 1968 |
Hydroxyurea in the treatment of chronic myeloid leukemia.
Topics: DNA; Humans; Hydroxyurea; Leukemia; Leukocytosis; Middle Aged; Splenomegaly | 1971 |